Zusammenfassung
Die Alzheimer-Krankheit ist die häufigste geriatrische Krankheit. 5% der über 65-Jährigen leiden daran. Diese Zahl steigt rapide mit dem Lebensalter an, und bei den über 80-Jährigen sind es schon über 10 bis 20%. Allerdings kann die Krankheit schon bei 35-Jährigen beginnen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
American Psychiatric Association (1995) 148th Annual Meeting. Topic 8: Organic Mental Disorders
Ballard CG (2002) Advances in the Treatment of Alzheimer’s Disease: Benefit of Dual Cholinesterase Inhibition. Eur Neurol 47:64–70
Bloom FE, Kupfer DJ (eds) (1995) Psychopharmacology. The Fourth Generation in Progress. Geriatric Disorders: 1361–1479; Raven, NY
Bullock R, Cameron A (2002) Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson’s Disease: A Case Series. Current Medical Research and Opinions 18(5):258–264
Chen P, Ratcliff G, Belle SH et al (2001) Patterns of Cognitive Decline in Presymptomatic Alzheimer Disease. Arch Gen Psychiatry 58:853–860
Clark R, Goate A (1993) Molecular genetics of Alzheimer’s disease. Arch Neurol 50:1164–1172
Cohen RM, Weingartner HW, Smallberg A, Pickar D, Murphy DL (1982) Effort and cognition in depression. Arch Gen Psychiatry 39:593–597
Collis A, Maruff P, Shafiq-Antonacci R et al (2001) Memory decline in healthy older people. Implication for identifying mild cognitive impairment. Neurology 56:1533–1538
Danyscz W, Parsons CG, Möbius HJ et al (2000) Neuroprotective and Symptomatological Action of Memantine Relevant for Alzheimer’s Disease — Unified Glutamatergic Hypothesis on the Mechanism of Action (1999) Neurotoxicity Research 2:85–97
Davis KL, Thal LJ, Gamzu E et al (1992) Tacrine in patients with Alzheimer’s disease: a double blind placebo controlled multicenter study. N Engl J Med 327:1374–1379
De Leon MJ (1999) An Atlas of Alzheimer’s Disease. The Encyclopedia of Visual Medicine Series. The Parthenon Publishing Group, New York London
Erkinjuntti T, Skoog I, Lane R, Andrews C (2002) Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. IJCP 56(10):791–796
Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 359:1283–1290
Feldman H, Gauthie S, Hecker J et al (2001) A 24 week, randomized double blind study of donepezil in moderate to severe Alzheimer’ disease. Neurology 57:613–620
Freeman TW, Clothier JL, Pazzaglia P et al (1992) A Double-blind Comparison of Valproate and Lithium in the Treatment of Acute Mania. Am J Psychiatry 149:108–111
Herrmann N (2001) Recommendations for the management of the behavioral and psychological symptoms of dementia. Can J Neurol Sci 28(suppl l):96–107
Hitzenberger G, Rameis H, Manigley C (1998) Pharmacological Properties of Piracetam. CNS Drugs 9(suppl l):19–27
Jackson G (ed) (2002) Cholinesterase inhibitors: relating pharmacological properties to clinical profiles. Int J Clin Practice, Suppl 127
MacLean LE, Collins CC, Byrne EJ (2001) Dementia with Lewy bodies treated with rivastigmine. Effects on cognition, neuropsychiatric symptoms and sleep. Int Psychogeriatr 13:277–288
Mega MS (2002) Differential Diagnosis of Dementia: Clinical Examination and Laboratory Assessment. http://www.medscape.com/viewarticle/439364_print
Mohs RC (1991) Assessment of cognitive symptoms in clinical studies of antidementia drugs (Homma A. trans). Jpn J Geriatr Psychiatry 2:1195–1201
Morris JC, Storandt M, Miller P et al (2001) Mild cognitive impairment represents early stage Alzheimer’s disease. Arch Neurol 58:397–405
Morris JC (2002) Is Mild Cognitive Impairment Simply Incipient Alzheimer’s Disease? 54th Annual Meeting Denver, April 13-20, 2002 2BS.005 Education Program
Nigel H, Greig NH et al (2001) A New Therapeutic Target in Alzheimer’s Disease Treatment: Attention to Butyrylcholinesterase. Current Medical Research and Opinion 17, no 3
Prasher VP, Huxley A, Haque MS (2002) A 24 week, double blind placebo controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease. Pilot study. Int J Geriatr Psychiatry 17:270–278
Pierpaoli W, Regelson W, Fabris N (eds) (1994) The Aging Clock. Ann NY Acad Sci 719
Rapoport SI, Grady CL (1993) Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer’s disease. J Neurosci 70:39–56
Reisberg B, Finkel S, Overall J et al (2001) The Alzheimer’s Disease Activities of Daily Living International Scale (ADL-IS). Int Psychogeriatr 13:163–181
Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that β-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248:492–495
Tariot P (2001) Current status and new developments with galantamine in the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2(12):2027–2049
Venneri A, Shanks MF, Staff RT et al (2002) Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease: Cognitive Neuroscience and Neuropsychology 13(l):83–87
Winblad B, Poritis N (1999) Memantine bei schwerer Demenz. Ergebnisse der M-BEST-Studie. Int J Geriat Psychiatry 14:135–146
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schmitz, M. (2004). Geriatrisch bedeutsame Substanzen. In: 1 × 1 der Psychopharmaka. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-7985-1927-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-7985-1927-5_5
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-7985-1394-5
Online ISBN: 978-3-7985-1927-5
eBook Packages: Springer Book Archive